Dominantly inherited Alzheimer's disease (AD) is an attractive model for study because the responsible mutations have known biochemical consequences that underlie the pathological basis of the disorder. The opportunity to determine the sequence of imaging and biomarker changes in asymptomatic gene carriers who are destined to develop AD may reveal critical information about the pathobiological cascade that culminates in symptomatic disease. Because the clinical and pathological phenotypes of autosomal dominant AD (ADAD) appear similar to those for the far more common late-onset sporadic AD, the nature and sequence of brain changes in ADAD also may be relevant for late-onset AD. However, individuals with ADAD are few and are geographically dispersed worldwide. In its initial funding period, the Dominantly Inherited Alzheimer's Network (DIAN) has established an international, multicenter registry of individuals (gene carriers and noncarriers; asymptomatic and symptomatic) who are biological adult children of a parent with a known causative mutation for AD in the amyloid precursor protein (APP), presenilin 1 (PSEN1), or presenilin 2 (PSEN2) genes in which the individuals are evaluated at entry and longitudinally thereafter with standard instruments to include the Uniform Data Set of the Alzheimer's Disease Centers, structural, functional, and amyloid imaging protocols developed by the Alzheimer's Disease Neuroimaging Initiative (ADNI), biological fluids (blood; CSF) in accordance with the ADNI protocols, and histopathological examination of cerebral tissue in individuals who come to autopsy also using ADNI protocols. In addition to establishing the DIAN registry, support was found for DIAN's major hypotheses examined. First, AD biomarker changes will identify MCs many years before these individuals develop symptomatic AD, thus supporting the concept of preclinical AD. Second, the initial biomarker changes in the preclinical stage of ADAD will involve A42, followed by changes related to neurodegeneration, followed by cognitive decline. Third, the clinical and neuropathological phenotypes of ADAD will be similar to, but not identical with, those of sporadic LOAD. Although data obtained in the initial budget period provide support for each of these hypotheses, all have yet to be confirmed with longitudinal data analyses. Hence, this application now emphasizes longitudinal data collection and analyses to truly appreciate how biomarkers change over time. This renewal application continues to address the 3 original DIAN hypotheses with increased emphasis on longitudinal data (increasing visit frequency for asymptomatic participants) and maintain current aims (maintenance of the established international DIAN registry of individuals (MCs and NCs, symptomatic and asymptomatic) with attention to preparing and adjusting for participants who participate in current and planned prevention trials. New scientific studies are planned; many funded independently of the DIAN grant and conducted within the DIAN infrastructure at no cost to DIAN.

Public Health Relevance

Alone among leading causes of death in the United States, Alzheimer disease (AD) lacks any effective treatment or prevention mechanism. The Dominantly Inherited Alzheimer Network (DIAN) provides a unique opportunity to understand the development of brain changes in AD, even many years before symptoms of the disease appear. Identifying this asymptomatic period also allows intervention with anti-AD drugs in an effort to prevent symptoms from ever occurring, a goal that is highly relevant not only to DIAN but also the far more common 'sporadic' form of AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Multi-Year Funded Research Project Cooperative Agreement (UF1)
Project #
3UF1AG032438-07S1
Application #
8912579
Study Section
Program Officer
Ryan, Laurie M
Project Start
2014-07-16
Project End
2019-12-31
Budget Start
2015-05-01
Budget End
2019-12-31
Support Year
7
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Washington University
Department
Neurology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Oxtoby, Neil P; Young, Alexandra L; Cash, David M et al. (2018) Data-driven models of dominantly-inherited Alzheimer's disease progression. Brain 141:1529-1544
Chhatwal, Jasmeer P; Schultz, Aaron P; Johnson, Keith A et al. (2018) Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. Brain 141:1486-1500
Franzmeier, Nicolai; Düzel, Emrah; Jessen, Frank et al. (2018) Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. Brain 141:1186-1200
Hsu, Simon; Gordon, Brian A; Hornbeck, Russ et al. (2018) Discovery and validation of autosomal dominant Alzheimer's disease mutations. Alzheimers Res Ther 10:67
Wang, Guoqiao; Berry, Scott; Xiong, Chengjie et al. (2018) A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Stat Med 37:3047-3055
Gordon, Brian A; Blazey, Tyler M; Su, Yi et al. (2018) Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol 17:241-250
Stout, Sarah H; Babulal, Ganesh M; Ma, Chunyu et al. (2018) Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. Alzheimers Dement 14:610-616
Villeneuve, Sylvia; Vogel, Jacob W; Gonneaud, Julie et al. (2018) Proximity to Parental Symptom Onset and Amyloid-? Burden in Sporadic Alzheimer Disease. JAMA Neurol 75:608-619
Lim, Yen Ying; Hassenstab, Jason; Goate, Alison et al. (2018) Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. Ann Neurol 84:424-435
Suárez-Calvet, Marc; Capell, Anja; Araque Caballero, Miguel Ángel et al. (2018) CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline. EMBO Mol Med 10:

Showing the most recent 10 out of 59 publications